Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

immunovant inc - IMVT

IMVT

Close Chg Chg %
26.18 1.17 4.47%

Closed Market

27.35

+1.17 (4.47%)

Volume: 1.81M

Last Updated:

Jan 14, 2026, 4:00 PM EDT

Trade Now

Company Overview: immunovant inc - IMVT

IMVT Key Data

Open

$26.08

 Day Range

25.73 - 27.37

52 Week Range

12.72 - 27.80

 Market Cap

$5.20B

Shares Outstanding

201.48M

 Public Float

66.04M

Beta

0.57

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$2.83

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.71M

  

IMVT Performance

1 Week
 
 0.58%
 
1 Month
 
 -0.91%
 
3 Months
 
 49.51%
 
1 Year
 
 9.72%
 
5 Years
 
 -40.63%
 

IMVT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 15
Full Ratings ➔

About immunovant inc - IMVT

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

IMVT At a Glance

Immunovant, Inc.
320 West 37th Street
New York, New York 10018
Phone 1-917-580-3099 Revenue 0.00
Industry Biotechnology Net Income -413,840,000.00
Sector Health Technology Employees 362
Fiscal Year-end 03 / 2026
View SEC Filings

IMVT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 4.109
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -4.286
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.00

IMVT Efficiency

Revenue/Employee N/A
Income Per Employee -1,143,204.42
Receivables Turnover N/A
Total Asset Turnover N/A

IMVT Liquidity

Current Ratio 11.162
Quick Ratio 11.162
Cash Ratio 10.381

IMVT Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -57.317
Return on Equity -62.457
Return on Total Capital -58.49
Return on Invested Capital -62.457

IMVT Capital Structure

Total Debt to Total Equity 0.014
Total Debt to Total Capital 0.014
Total Debt to Total Assets 0.013
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Immunovant Inc - IMVT

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
1.23M 1.32M 231.00K 377.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.23M 1.32M 231.00K 377.00K
Depreciation
1.23M 1.32M 231.00K 377.00K
Amortization of Intangibles
- - - -
-
COGS Growth
+23.45% +7.47% -82.55% +63.20%
Gross Income
(1.23M) (1.32M) (231.00K) (377.00K)
Gross Income Growth
-23.45% -7.47% +82.55% -63.20%
Gross Profit Margin
- - - -
-
2022 2023 2024 2025 5-year trend
SG&A Expense
154.80M 206.95M 269.98M 437.77M
Research & Development
101.81M 160.26M 212.93M 360.92M
Other SG&A
52.99M 46.70M 57.05M 76.86M
SGA Growth
+44.51% +33.69% +30.45% +62.15%
Other Operating Expense
- - - -
-
Unusual Expense
- - 10.00M 12.50M
-
EBIT after Unusual Expense
(156.03M) (218.28M) (282.71M) (438.15M)
Non Operating Income/Expense
(781.00K) 7.33M 23.94M 25.20M
Non-Operating Interest Income
- 7.58M 24.95M 24.73M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(156.81M) (210.95M) (258.77M) (412.95M)
Pretax Income Growth
-45.48% -34.52% -22.67% -59.58%
Pretax Margin
- - - -
-
Income Tax
(84.00K) 9.00K 567.00K 891.00K
Income Tax - Current - Domestic
(84.00K) 9.00K 567.00K 891.00K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(156.73M) (210.96M) (259.34M) (413.84M)
Minority Interest Expense
- - - -
-
Net Income
(156.73M) (210.96M) (259.34M) (413.84M)
Net Income Growth
-45.89% -34.60% -22.93% -59.58%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(156.73M) (210.96M) (259.34M) (413.84M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(156.73M) (210.96M) (259.34M) (413.84M)
EPS (Basic)
-1.429 -1.7141 -1.8779 -2.7303
EPS (Basic) Growth
-16.73% -19.95% -9.56% -45.39%
Basic Shares Outstanding
109.68M 123.08M 138.10M 151.57M
EPS (Diluted)
-1.429 -1.7141 -1.8779 -2.7303
EPS (Diluted) Growth
-16.73% -19.95% -9.56% -45.39%
Diluted Shares Outstanding
109.68M 123.08M 138.10M 151.57M
EBITDA
(154.80M) (206.95M) (269.98M) (437.77M)
EBITDA Growth
-44.51% -33.69% -30.45% -62.15%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 41.533
Number of Ratings 15 Current Quarters Estimate -0.729
FY Report Date 03 / 2026 Current Year's Estimate -2.859
Last Quarter’s Earnings -0.74 Median PE on CY Estimate N/A
Year Ago Earnings -2.73 Next Fiscal Year Estimate -2.985
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 14 8 14 12
Mean Estimate -0.73 -0.72 -2.86 -2.99
High Estimates -0.55 -0.55 -2.24 -2.14
Low Estimate -0.94 -0.92 -3.21 -3.95
Coefficient of Variance -16.39 -18.48 -9.18 -18.49

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 12 12 12
OVERWEIGHT 0 0 0
HOLD 3 3 5
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Overweight

Insider Actions for Immunovant Inc - IMVT

Date Name Shares Transaction Value
Jan 12, 2026 Jay S. Stout Chief Technology Officer 199,666 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $26.51 per share 5,293,145.66
Jan 12, 2026 Jay S. Stout Chief Technology Officer 199,611 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $26.92 per share 5,373,528.12
Apr 18, 2025 Eva Renee Barnett Chief Financial Officer 396,774 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $14.89 per share 5,907,964.86
Apr 18, 2025 Peter Salzmann Chief Executive Officer; Director 1,178,191 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $14.89 per share 17,543,263.99
Apr 4, 2025 Tuyl Christopher Van Chief Legal Officer 71,531 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 George V. Migausky Director 137,251 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Melanie Gloria Chief Operating Officer 107,297 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Melanie Gloria Chief Operating Officer 186,137 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Eva Renee Barnett Chief Financial Officer 125,180 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Peter Salzmann Chief Executive Officer; Director 374,395 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Michael Geffner Chief Medical Officer 143,063 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Michael Geffner Chief Medical Officer 233,888 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Frank M. Torti Director 93,599 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Frank M. Torti Director 835,039 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Atul C. Pande Director 7,600 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Atul C. Pande Director 102,851 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Douglas Hughes Director 7,600 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Douglas Hughes Director 135,773 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Andrew J. Fromkin Director 7,600 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Andrew J. Fromkin Director 108,101 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Immunovant Inc in the News